TGF-β pathway as a therapeutic target in bone metastases

Patricia Juárez, Theresa Guise

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β ) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

Original languageEnglish
Pages (from-to)1301-1312
Number of pages12
JournalCurrent Pharmaceutical Design
Volume16
Issue number11
StatePublished - Apr 2010

Fingerprint

Transforming Growth Factors
Neoplasm Metastasis
Bone and Bones
Neoplasms
Therapeutics
Breast Neoplasms
Growth Inhibitors
Epithelial-Mesenchymal Transition
Bone Development
Skeleton
Immunosuppression
Prostatic Neoplasms

Keywords

  • Bone
  • Bone metastases
  • Breast cancer
  • Melanoma
  • Metastases
  • Prostatic cancer
  • TGF-β
  • TGF-β inhibitors
  • TGF-β receptors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

TGF-β pathway as a therapeutic target in bone metastases. / Juárez, Patricia; Guise, Theresa.

In: Current Pharmaceutical Design, Vol. 16, No. 11, 04.2010, p. 1301-1312.

Research output: Contribution to journalArticle

@article{9560e1eb63384bb3a33cc89a20a9c494,
title = "TGF-β pathway as a therapeutic target in bone metastases",
abstract = "Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β ) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.",
keywords = "Bone, Bone metastases, Breast cancer, Melanoma, Metastases, Prostatic cancer, TGF-β, TGF-β inhibitors, TGF-β receptors",
author = "Patricia Ju{\'a}rez and Theresa Guise",
year = "2010",
month = "4",
language = "English",
volume = "16",
pages = "1301--1312",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - TGF-β pathway as a therapeutic target in bone metastases

AU - Juárez, Patricia

AU - Guise, Theresa

PY - 2010/4

Y1 - 2010/4

N2 - Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β ) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

AB - Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β ) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

KW - Bone

KW - Bone metastases

KW - Breast cancer

KW - Melanoma

KW - Metastases

KW - Prostatic cancer

KW - TGF-β

KW - TGF-β inhibitors

KW - TGF-β receptors

UR - http://www.scopus.com/inward/record.url?scp=77950878893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950878893&partnerID=8YFLogxK

M3 - Article

C2 - 20166977

AN - SCOPUS:77950878893

VL - 16

SP - 1301

EP - 1312

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -